Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: An open-label prospective trial
Introduction: The combination therapy of aliskiren and renin–angiotensin–aldosterone system (RAAS) blocker in chronic kidney disease (CKD) is controversial. Whether such dual blockade can effectively apply to patients with CKD irrespective of stage and amount of proteinuria remains uncertain. Method...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2014-09-01
|
| Series: | Journal of the Renin-Angiotensin-Aldosterone System |
| Online Access: | https://doi.org/10.1177/1470320312467560 |